Advertisement
U.S. Markets closed

ReShape Lifesciences Inc. (RSLS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.1636+0.0011 (+0.68%)
At close: 04:00PM EDT
0.1663 +0.00 (+1.65%)
After hours: 07:49PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close0.1625
Open0.1685
Bid0.1800 x 900
Ask0.1804 x 1200
Day's Range0.1611 - 0.1706
52 Week Range0.1410 - 4.1000
Volume217,337
Avg. Volume1,117,876
Market Cap3.838M
Beta (5Y Monthly)1.18
PE Ratio (TTM)N/A
EPS (TTM)-38.5600
Earnings DateApr 15, 2024 - Apr 19, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for RSLS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ReShape Lifesciences, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/23/2021The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    3 years agoArgus Research
View more
  • GlobeNewswire

    ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX

    2024 Operating Expenses Expected to Decrease by 55.4% Compared to 2023 Company Reaffirms Commitment to Profitability High Priority Search for Synergistic M&A Partner Continues IRVINE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced a 2024 cost reduction plan and reorganization to prioritize the commercialization of the company’s next generation, enhanced Lap-Band® 2.0 FL

  • GlobeNewswire

    ReShape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band® 2.0 FLEX

    FLEX Technology Designed to Enhance the Patient Experience Surgeon Training Underway for the Initial Launch of the Lap-Band® 2.0 FLEX IRVINE, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Adam Smith, D.O., Bariatric Surgery Specialist and Chief Executive Officer of Ultimate Bariatrics in Dallas, Fort Worth, TX, and Christine Ren-Fielding, M.D., Professor of Surgery

  • GlobeNewswire

    ReShape Lifesciences® Conducts Bariatric Fellows Training for its Lap-Band® System, Highlighting the Next-Generation Lap-Band® 2.0 FLEX

    First Time Introduction of Lap-Band® 2.0 FLEX to the Next Generation of SurgeonsIRVINE, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that bariatric surgical fellows from the University of Texas Health Center in Houston, Texas were trained on Friday, January 19th, on the Lap-Band® System and also received an introduction to the Company’s new Lap-Band® 2.0 FLEX. The trai